Source:http://linkedlifedata.com/resource/pubmed/id/10102629
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
8
|
pubmed:dateCreated |
1999-4-22
|
pubmed:abstractText |
In order to test if the carboxyl terminal polypeptide of the Retinoblastoma (Rb) tumor suppressor protein, could be used to suppress the growth factor-independent growth phenotype of p210bcr-abl positive myeloid cells, we introduced a truncated form of the 3' end of the Rb cDNA encoding its last 173 amino acid residues (Rb C-box) which localize into the cytoplasm where the p210bcr-abl transforming protein is found, into myeloid cells (32D) which depends on the p210bcr-abl protein for IL3 growth factor-independent growth (32D-p210). The expression of the plasmid vectors carrying the Rb C-box cDNAs was shown to inhibit the abl tyrosine specific protein kinase activity of the p210(bcr-abl) oncoprotein and to suppress the IL3-independent growth phenotype of the 32D-p210 cells. The Rb C-box polypeptides did not suppress the growth of the untransfected 32D parental cell line in methylcellulose in the presence of IL3-conditioned medium. These results suggest that the cytoplasmic localization of the p210(bcr-abl) allows it to escape the effect of intranuclear proteins such as Rb which negatively regulate the p145(c-abl) kinase.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Complementary,
http://linkedlifedata.com/resource/pubmed/chemical/Fusion Proteins, bcr-abl,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-3,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Fusion Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Retinoblastoma Protein,
http://linkedlifedata.com/resource/pubmed/chemical/Tetracycline
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0950-9232
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
25
|
pubmed:volume |
18
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1589-95
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:10102629-Animals,
pubmed-meshheading:10102629-Cell Transformation, Neoplastic,
pubmed-meshheading:10102629-Colony-Forming Units Assay,
pubmed-meshheading:10102629-DNA, Complementary,
pubmed-meshheading:10102629-Fusion Proteins, bcr-abl,
pubmed-meshheading:10102629-Genes, Retinoblastoma,
pubmed-meshheading:10102629-Humans,
pubmed-meshheading:10102629-Interleukin-3,
pubmed-meshheading:10102629-Peptide Fragments,
pubmed-meshheading:10102629-Recombinant Fusion Proteins,
pubmed-meshheading:10102629-Retinoblastoma Protein,
pubmed-meshheading:10102629-Tetracycline,
pubmed-meshheading:10102629-Transcription, Genetic,
pubmed-meshheading:10102629-Transfection
|
pubmed:year |
1999
|
pubmed:articleTitle |
The presence of the Rb c-box peptide in the cytoplasm inhibits p210bcr-abl transforming function.
|
pubmed:affiliation |
Department of Internal Medicine, Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06520, USA.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|